Association of p73 G4C14-to-A4T14 polymorphism with non-small cell lung cancer risk

Wang,Shuang  Shuang; Zhu,Xiang  Qin; Yang,Shao  Di; Dong,Lin  Li; Li,Wen; Tang,Jianxin

doi:10.3892/ol.2015.3322

Association of p73 G4C14-to-A4T14 polymorphism with non-small cell lung cancer risk

Authors:
- Shuang Shuang Wang
- Xiang Qin Zhu
- Shao Di Yang
- Lin Li Dong
- Wen Li
- Jianxin Tang
View Affiliations

Affiliations: Key Laboratory of Green Packaging and Application of Biological Nanotechnology, Hunan University of Technology, Zhuzhou, Hunan 412008, P.R. China, Department of Pathology, Hunan Provincial Tumor Hospital, Changsha, Hunan 410113, P.R. China, Institute of Biomedical Engineering, School of Geosciences and Info‑Physics, Central South University, Changsha, Hunan 410006, P.R. China
Published online on: June 4, 2015 https://doi.org/10.3892/ol.2015.3322
Pages: 995-999

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The p73 gene is a structural and functional homolog of the p53 gene, which has a crucial role in mediating cell cycle arrest and apoptosis. Numerous previous studies have investigated the polymorphism of p73 G4C14‑to‑A4T14 at exon 2, as it was suggested to affect gene expression and result in functional significance. However, the correlation of this polymorphism with clinicopathological variables of patients with non‑small cell lung cancer (NSCLC) remains to be elucidated. The aim of the present study was to examine the association between the gene polymorphism of p73 G4C14‑to‑A4T14 and the risk of developing NSCLC. The single‑nucleotide polymorphisms of p73 G4C14‑to‑A4T14 were genotyped using polymerase chain reaction with confronting two‑pair primers and direct DNA sequencing in 186 NSCLC patients and 196 cancer‑free controls. χ2‑tests and logistic regression analysis were used to analyze the experimental data, including the determination of odds ratio (OR), 95% confidence intervals (95% CIs) and P‑values. The results demonstrated that the AT/AT genotype was associated with a significantly decreased risk of NSCLC (P=0.010; OR=0.370; 95% CI=0.170‑0.806) compared with the GC allele genotypes including GC/GC and GC/AT. In addition, carriers of the AT allele exhibited a significantly reduced risk of NSCLC (P=0.038; OR=0.713; 95% CI=0.517‑0.983) compared with non‑carriers. In conclusion, these results indicated that the p73 G4C14‑to‑A4T14 polymorphism was a potential marker of NSCLC genetic susceptibility. However, further studies with a larger population are required in order to confirm these results.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kaghad M, Bonnet H, Yang A, et al: Monoallelically expressed gene related to p53 at lp36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:809–819. 1997. View Article : Google Scholar : PubMed/NCBI
3	Bénard J, Douc-Rasy S and Ahomadegbe JC: TP53 family members and human cancers. Hum Mutat. 21:182–191. 2003. View Article : Google Scholar : PubMed/NCBI
4	Moll UM, Erster S and Zaika A: p53, p63 and p73 - solos, alliances and feuds among family members. Biochim Biophys Acta. 1552:47–59. 2001.PubMed/NCBI
5	Shibukawa K, Miyokawa N, Tokusashi Y, et al: High incidence of chromosomal abnormalities at lp36 and 9p21 in early-stage central type squamous cell carcinoma and squamous dysplasia of bronchus detected by autofluorescence bronchoscopy. Oncol Rep. 22:81–87. 2009.PubMed/NCBI
6	Uramoto H, Sugio K, Oyama T, et al: Expression of the p53 family in lung cancer. Anticancer Res. 26:1785–1790. 2006.PubMed/NCBI
7	Liu K, Zhan M and Zheng P: Loss of p73 expression in six non-small cell lung cancer cell lines is associated with 5′CpG island methylation. Exp Mol Pathol. 84:59–63. 2008. View Article : Google Scholar : PubMed/NCBI
8	Lo Iacono M, Monica V, Saviozzi S, et al: p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. J Thorac Oncol. 6:473–481. 2011. View Article : Google Scholar : PubMed/NCBI
9	Nyman U, Sobczak-Pluta A, Vlachos P, et al: Full-length p73alpha represses drug-induced apoptosis in small cell lung carcinoma cells. J Biol Chem. 280:34159–34169. 2005. View Article : Google Scholar : PubMed/NCBI
10	Zhang X, Li X, Wu Z, et al: The p73 G4C14-to-A4T14 polymorphism is associated with risk of lung cancer in the Han nationality of North China. Mol Carcinog. 52:387–391. 2013. View Article : Google Scholar : PubMed/NCBI
11	Tokuchi Y, Hashimoto T, Kobayashi Y, et al: The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Br J Cancer. 80:1623–1629. 1999. View Article : Google Scholar : PubMed/NCBI
12	Li Q, Athan E, S, Wei M, et al: TP73 allelic expression in human brain and allele frequencies in Alzheimer's disease. BMC Med Genet. 5:5–14. 2004. View Article : Google Scholar : PubMed/NCBI
13	Li GJ, Sturgis EM, Wang LE, et al: Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 25:1911–1916. 2004. View Article : Google Scholar : PubMed/NCBI
14	Ryan BM, McManus R, Daly JS, et al: A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinamo. Br J Cancer. 85:1499–1503. 2001. View Article : Google Scholar : PubMed/NCBI
15	Hu Z, Miao X, Ma H, et al: Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer. 114:455–460. 2005. View Article : Google Scholar : PubMed/NCBI
16	Li G, Wang LE, Chamberlain RM, et al: p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res. 64:6863–6866. 2004. View Article : Google Scholar : PubMed/NCBI
17	Choi JE, Kang HG, Chae MH, et al: No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population. Biochem Genet. 44:533–540. 2006. View Article : Google Scholar
18	Hiraki A, Matsuo K, Hamajima N, et al: Different risk relations with smoking for non-small cell lung cancer: Comparison of TP53 and TP73 genotypes. Asian Pac J Cancer Prev. 4:107–112. 2003.PubMed/NCBI
19	Lee KE, Hong YS, Kim BG, et al: p73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival. World J Gastroenterol. 16:4448–4454. 2010. View Article : Google Scholar : PubMed/NCBI
20	Melino G, De Laurenzi V and Vousden KH: p73: Friend or foe in tumorigenesis. Nat Rev Cancer. 2:605–615. 2002. View Article : Google Scholar : PubMed/NCBI
21	Grob TJ, Novak U, Maisse C, et al: Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 8:1213–1223. 2001. View Article : Google Scholar : PubMed/NCBI
22	Ishimoto O, Kawahara C, Enjo K, et al: Possible oncogenic potential of DeltaNp73: A newly identified isoform of human p73. Cancer Res. 62:636–641. 2002.PubMed/NCBI
23	Tomasini R, Tsuchihara K, Wilhelm M, et al: TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 22:2677–2691. 2008. View Article : Google Scholar : PubMed/NCBI
24	Concin N, Becker K, Slade N, et al: Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their roles as epigenetic p53 inhibits in vivo. Cancer Res. 64:2449–2460. 2004. View Article : Google Scholar : PubMed/NCBI